6.3.4. systemic salvage treatment relapse refractory disease. cisplatin combination salvage chemotherapy result long-term remissions approximately 50% patients relapse first-line chemotherapy. results highly dependent several prognostic factors . regimens choice four cycles three-agent regimen including cisplatin ifosfamide plus third drug: etoposide (vip), paclitaxel (tip), potentially gemcitabine (gip) (table 7) . rct compared regimens. due potential risk lethal haematological toxicity, regimens used g-csf support well-trained oncologists. table 7: standard vip, tip gip salvage chemotherapy (interval 21 days) regimenchemotherapy agentsdosageduration cyclesvipcisplatin*etoposideifosfamide*20 mg/m275-100 mg/m21.2 g/m2days 1-5days 1-5days 1-5tippaclitaxelifosfamide*cisplatin*250 mg/m2 xx1.5 g/ m225 mg/m224 hour continuous infusion day 1days 2-5days 2-5alternative schedulepaclitaxelifosfamide*cisplatin*175 mg/m21.2 g/m220 mg/m2day 1, 3 hour infusiondays 1-5days 1-5gipgemcitabineifosfamidecisplatin1000 mg/m21200 mg/m220 mg/m2day 1 + 5days 1-5days 1-5 xx mrc schedule uses paclitaxel 175 mg/m2 3 hour infusion infusion please refer appendix 4 – chemotherapeutic protocols https://uroweb.org/guidelines/testicular-cancer/publications-appendices detailed information. retrospective analysis international prognostic factors study group (ipfsg) evaluated risk relapse patients occurred least three cisplatin cycles subsequent cisplatin conventional-dose carboplatin-based high-dose salvage chemotherapy . seven variables: histology, primary tumour location, response, progression-free interval first-line treatment level afp, β-hcg presence liver, bone brain metastasis salvage treatment, identified independent prognostic variables relapse initial cisplatin chemotherapy . using factors, five risk-groups: low-risk = -1 points; low-risk = 0 points; intermediate-risk = 1-2 points; high-risk = 3-4 points; high-risk > 5 points; identified significant differences pfs os. table 9 illustrates five risk groups corresponding two-year pfs three-year os rates . several recent trials validated scoring system [247-250]. first-line therapy, prognostic impact tumour marker decline applies salvage setting . progression induction chemotherapy negative os, prior use paclitaxel significantly associated negative outcome . secondary analysis ipfsg cohort (n = 1,600 patients) showed 10-15% improvement os prognostic subgroups treated high-dose salvage therapy compared standard dose therapy. evaluated rct hdct vs. conventional dose chemotherapy patients first-line relapse underway (tiger trial). hdct used salvage treatment, sequential treatment cycles high-dose carboplatin etoposide (hd-ce) preferred single high-dose regimen former associated less toxicity-related deaths . recent sr confirmed superiority using least two high-dose cycles salvage setting single high-dose cycle . clearly utmost importance rare patients relapse treated within clinical trials specialised centres. table 8: international prognostic factors study group score seminoma non-seminoma relapse cisplatin-based first-line chemotherapy points-10123variablehistologyseminomanon-seminomaprimary sitegonadalretroperitonealmediastinalresponsecr/prm-prm+/sdpdpfi> 3 months< 3 monthsafp salvagenormal< 10001000hcg salvage< 10001000lbbnoyes afp = alpha-fetoprotein; cr = complete remission; prm- = partial remission, negative markers; prm+ = partial remission, positive markers; hcg = human chorionic gonadotrophin; lbb = liver, bone, brain metastases; pd = progressive disease; pfi = progression-free interval; sd = stable disease. table 9: pfs os estimates patients according igcccg prognostic score seminoma non-seminoma relapse cisplatin-based first-line chemotherapy score (n = 1,435)n%hr2-years pfs (%)3-year os (%)very low765.30175.177.0low25717.92.0752.669.0intermediate64645.02.8842.857.3high35124.54.8126.431.7very high1057.38.9511.514.7missing159---- hr = hazard ratio; pfs = progression-free survival; n = number patients; os = overall survival.